KR101926442B1 - 키메라 주요 조직적합성 복합체 （ｍｈｃ） ｉｉ 분자들을 발현하는 유전자 변형된 마우스 - Google Patents
키메라 주요 조직적합성 복합체 （ｍｈｃ） ｉｉ 분자들을 발현하는 유전자 변형된 마우스 Download PDFInfo
- Publication number
- KR101926442B1 KR101926442B1 KR1020147014315A KR20147014315A KR101926442B1 KR 101926442 B1 KR101926442 B1 KR 101926442B1 KR 1020147014315 A KR1020147014315 A KR 1020147014315A KR 20147014315 A KR20147014315 A KR 20147014315A KR 101926442 B1 KR101926442 B1 KR 101926442B1
- Authority
- KR
- South Korea
- Prior art keywords
- mhc
- human
- chimeric
- alpha
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title claims description 400
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title claims description 393
- 241000699670 Mus sp. Species 0.000 title description 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 220
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 189
- 229920001184 polypeptide Polymers 0.000 claims abstract description 171
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 137
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 53
- 239000002773 nucleotide Substances 0.000 claims description 101
- 125000003729 nucleotide group Chemical group 0.000 claims description 101
- 210000004027 cell Anatomy 0.000 claims description 98
- 241000283984 Rodentia Species 0.000 claims description 85
- 241001529936 Murinae Species 0.000 claims description 43
- 230000001086 cytosolic effect Effects 0.000 claims description 43
- 108010046732 HLA-DR4 Antigen Proteins 0.000 claims description 33
- 230000001105 regulatory effect Effects 0.000 claims description 14
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 claims description 12
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 108010053491 HLA-DR beta-Chains Proteins 0.000 claims description 10
- 230000035515 penetration Effects 0.000 claims description 10
- 108010010378 HLA-DP Antigens Proteins 0.000 claims description 8
- 102000015789 HLA-DP Antigens Human genes 0.000 claims description 8
- 210000001161 mammalian embryo Anatomy 0.000 claims description 8
- 101150087698 alpha gene Proteins 0.000 claims description 7
- 230000001131 transforming effect Effects 0.000 claims description 4
- 108700005092 MHC Class II Genes Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 36
- 210000002257 embryonic structure Anatomy 0.000 abstract description 7
- 210000000987 immune system Anatomy 0.000 abstract description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 147
- 235000018102 proteins Nutrition 0.000 description 63
- 239000000427 antigen Substances 0.000 description 53
- 108091007433 antigens Proteins 0.000 description 53
- 102000036639 antigens Human genes 0.000 description 53
- 241000700159 Rattus Species 0.000 description 39
- 210000001744 T-lymphocyte Anatomy 0.000 description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 description 23
- 238000006467 substitution reaction Methods 0.000 description 21
- 239000013598 vector Substances 0.000 description 21
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 19
- 108010058597 HLA-DR Antigens Proteins 0.000 description 18
- 230000008685 targeting Effects 0.000 description 18
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 17
- 108700028369 Alleles Proteins 0.000 description 17
- 102000006354 HLA-DR Antigens Human genes 0.000 description 17
- 230000028993 immune response Effects 0.000 description 17
- 108091054438 MHC class II family Proteins 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 15
- 210000000612 antigen-presenting cell Anatomy 0.000 description 15
- 238000012217 deletion Methods 0.000 description 14
- 230000037430 deletion Effects 0.000 description 14
- 108091008874 T cell receptors Proteins 0.000 description 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 108700024394 Exon Proteins 0.000 description 12
- 241000282412 Homo Species 0.000 description 12
- 150000007523 nucleic acids Chemical group 0.000 description 12
- 102000043131 MHC class II family Human genes 0.000 description 11
- 208000023275 Autoimmune disease Diseases 0.000 description 10
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 10
- 229930193140 Neomycin Natural products 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 229960004927 neomycin Drugs 0.000 description 10
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 7
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 7
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 102000007079 Peptide Fragments Human genes 0.000 description 6
- 108010033276 Peptide Fragments Proteins 0.000 description 6
- 230000030741 antigen processing and presentation Effects 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 101150062179 II gene Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004292 cytoskeleton Anatomy 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 210000005220 cytoplasmic tail Anatomy 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 238000011714 129 mouse Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108091008109 Pseudogenes Proteins 0.000 description 3
- 102000057361 Pseudogenes Human genes 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000034512 ubiquitination Effects 0.000 description 3
- 238000010798 ubiquitination Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 2
- 101150035620 HLA-DRA gene Proteins 0.000 description 2
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 2
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 2
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 2
- 101000968009 Homo sapiens HLA class II histocompatibility antigen, DR alpha chain Proteins 0.000 description 2
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 2
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101100450101 Mus musculus H2-Ea gene Proteins 0.000 description 2
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 241000121210 Sigmodontinae Species 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 241001105470 Valenzuela Species 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002121 endocytic effect Effects 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 102000055647 human CSF2RB Human genes 0.000 description 2
- 238000011577 humanized mouse model Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 108010028930 invariant chain Proteins 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WHRZCXAVMTUTDD-UHFFFAOYSA-N 1h-furo[2,3-d]pyrimidin-2-one Chemical compound N1C(=O)N=C2OC=CC2=C1 WHRZCXAVMTUTDD-UHFFFAOYSA-N 0.000 description 1
- WELIVEBWRWAGOM-UHFFFAOYSA-N 3-amino-n-[2-[2-(3-aminopropanoylamino)ethyldisulfanyl]ethyl]propanamide Chemical compound NCCC(=O)NCCSSCCNC(=O)CCN WELIVEBWRWAGOM-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 0 CC[C@@]([C@@](C1)C11CC(C2)(CC2C(C)=*)C1)NC Chemical compound CC[C@@]([C@@](C1)C11CC(C2)(CC2C(C)=*)C1)NC 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 241000398949 Calomyscidae Species 0.000 description 1
- 241000700193 Calomyscus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000008138 Composite lymphoma Diseases 0.000 description 1
- 241000398985 Cricetidae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241001095404 Dipodoidea Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000289659 Erinaceidae Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 241001416537 Gliridae Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010047762 HLA-DQ8 antigen Proteins 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 101150018610 HLA-DRB1 gene Proteins 0.000 description 1
- 108010029657 HLA-DRB1*04:01 antigen Proteins 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000986087 Homo sapiens HLA class I histocompatibility antigen, B alpha chain Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101000968028 Homo sapiens HLA class II histocompatibility antigen, DRB1 beta chain Proteins 0.000 description 1
- 101001030243 Homo sapiens Myosin-7 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 244000073231 Larrea tridentata Species 0.000 description 1
- 235000006173 Larrea tridentata Nutrition 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 241000398750 Muroidea Species 0.000 description 1
- 101001082628 Mus musculus H-2 class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101100123457 Mus musculus H2-Ab1 gene Proteins 0.000 description 1
- 241000398990 Nesomyidae Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241001338313 Platacanthomyidae Species 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000398956 Spalacidae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 150000001294 alanine derivatives Chemical class 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 101150062912 cct3 gene Proteins 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960002126 creosote Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 101150067757 ea gene Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000048974 human HLA-B Human genes 0.000 description 1
- 102000056867 human MYH7 Human genes 0.000 description 1
- 230000009403 human autoimmunity Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 244000000011 human parasite Species 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552584P | 2011-10-28 | 2011-10-28 | |
| US61/552,584 | 2011-10-28 | ||
| PCT/US2012/062029 WO2013063340A1 (en) | 2011-10-28 | 2012-10-26 | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187034955A Division KR102113108B1 (ko) | 2011-10-28 | 2012-10-26 | 키메라 주요 조직적합성 복합체 （ｍｈｃ） 제ｉｉ부류 분자들을 발현하는 유전자전이 마우스 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140089558A KR20140089558A (ko) | 2014-07-15 |
| KR101926442B1 true KR101926442B1 (ko) | 2018-12-12 |
Family
ID=47430036
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147014315A Active KR101926442B1 (ko) | 2011-10-28 | 2012-10-26 | 키메라 주요 조직적합성 복합체 （ｍｈｃ） ｉｉ 분자들을 발현하는 유전자 변형된 마우스 |
| KR1020187034955A Active KR102113108B1 (ko) | 2011-10-28 | 2012-10-26 | 키메라 주요 조직적합성 복합체 （ｍｈｃ） 제ｉｉ부류 분자들을 발현하는 유전자전이 마우스 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187034955A Active KR102113108B1 (ko) | 2011-10-28 | 2012-10-26 | 키메라 주요 조직적합성 복합체 （ｍｈｃ） 제ｉｉ부류 분자들을 발현하는 유전자전이 마우스 |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US8847005B2 (enExample) |
| EP (4) | EP2770822B9 (enExample) |
| JP (2) | JP6285361B2 (enExample) |
| KR (2) | KR101926442B1 (enExample) |
| CN (3) | CN108401986B (enExample) |
| AU (4) | AU2012327205B2 (enExample) |
| BR (1) | BR112014009941B1 (enExample) |
| CA (1) | CA2852962C (enExample) |
| CY (3) | CY1119283T1 (enExample) |
| DK (3) | DK2770822T3 (enExample) |
| ES (3) | ES2914374T3 (enExample) |
| HR (3) | HRP20171327T1 (enExample) |
| HU (2) | HUE034374T2 (enExample) |
| IL (3) | IL231895B (enExample) |
| IN (1) | IN2014CN03892A (enExample) |
| LT (3) | LT2770822T (enExample) |
| MX (2) | MX355726B (enExample) |
| PL (3) | PL3272214T3 (enExample) |
| PT (3) | PT2770822T (enExample) |
| RS (3) | RS63220B1 (enExample) |
| RU (1) | RU2660564C2 (enExample) |
| SG (3) | SG10201510056SA (enExample) |
| SI (3) | SI3590332T1 (enExample) |
| SM (3) | SMT202200205T1 (enExample) |
| WO (1) | WO2013063340A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008054865A2 (en) | 2006-04-26 | 2008-05-08 | L-3 Communications Security And Detection Systems, Inc. | Multi-source surveillance systems |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| RU2751240C2 (ru) | 2011-10-28 | 2021-07-12 | Регенерон Фармасьютикалс, Инк. | Гуманизированные il-6 и рецептор il-6 |
| SG10201510056SA (en) | 2011-10-28 | 2016-01-28 | Regeneron Pharma | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
| CA2900832A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| JP6444321B2 (ja) | 2013-02-22 | 2018-12-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヒト化主要組織適合性遺伝子複合体を発現するマウス |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| AU2014249148B2 (en) | 2013-03-11 | 2020-04-02 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
| SMT202500280T1 (it) | 2013-09-23 | 2025-09-12 | Regeneron Pharma | Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale |
| TR201904342T4 (tr) * | 2013-10-15 | 2019-05-21 | Regeneron Pharma | Hümani̇ze il-15 hayvanlar |
| EP3071024B1 (en) | 2013-11-19 | 2018-09-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| SMT202000332T1 (it) | 2014-04-08 | 2020-07-08 | Regeneron Pharma | Animali non umani aventi recettori fc-gamma umanizzati |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| DK3157956T3 (da) | 2014-06-19 | 2020-04-27 | Regeneron Pharma | Ikke-humane dyr med et humaniseret gen med programmeret celledød 1 |
| KR20170083534A (ko) | 2014-09-19 | 2017-07-18 | 리제너론 파마슈티칼스 인코포레이티드 | 키메라 항원 수용체 |
| BR112017010793A2 (pt) | 2014-11-24 | 2017-12-26 | Regeneron Pharma | animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo. |
| ES2969389T3 (es) | 2014-12-05 | 2024-05-17 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado |
| EP4399969A3 (en) | 2014-12-09 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
| AU2016246698B2 (en) | 2015-04-06 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
| PT3376857T (pt) | 2015-11-20 | 2021-05-27 | Regeneron Pharma | Animais não humanos com um gene humanizado 3 de ativação de linfócitos |
| US10582702B2 (en) * | 2016-02-04 | 2020-03-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered ANGPTL8 gene |
| CA3014645C (en) | 2016-02-29 | 2022-10-25 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized tmprss gene |
| IL263160B2 (en) | 2016-06-03 | 2024-01-01 | Regeneron Pharma | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
| JP7361031B2 (ja) | 2017-11-30 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物 |
| SMT202500038T1 (it) | 2018-03-24 | 2025-03-12 | Regeneron Pharma | Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo |
| KR20250121150A (ko) | 2018-03-26 | 2025-08-11 | 리제너론 파마슈티칼스 인코포레이티드 | 치료제를 시험하기 위한 인간화된 설치류 |
| HUE067361T2 (hu) | 2018-07-16 | 2024-10-28 | Regeneron Pharma | Ditra betegség rágcsáló modelljei és alkalmazásaik |
| WO2021081156A1 (en) * | 2019-10-22 | 2021-04-29 | The Trustees Of Columbia University In The City Of New York | Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice |
| WO2021113297A1 (en) | 2019-12-02 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
| IL307238A (en) | 2021-03-31 | 2023-11-01 | Regeneron Pharma | Transgenic mice containing human components of the cellular immune system with an enhanced diversity of the TCRB repertoire |
| CA3258639A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharma | Multispecific molecules to modulate T lymphocyte activity, and their uses |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| EP4590120A1 (en) | 2022-09-22 | 2025-07-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice expressing components of human cellular immune system |
| US20250339384A1 (en) | 2023-01-27 | 2025-11-06 | Regeneron Pharmaceuticals, Inc. | Modified rhabdovirus glycoproteins and uses thereof |
| WO2025064470A1 (en) | 2023-09-19 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Viral peptides and uses thereof |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| WO2025136809A2 (en) | 2023-12-19 | 2025-06-26 | Regeneron Pharmaceuticals, Inc. | Foxp3 peptides and uses thereof |
| WO2025178991A1 (en) | 2024-02-21 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Splicing factor gene mutation-associated neoantigenic peptides and uses thereof |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070209083A1 (en) | 2001-07-13 | 2007-09-06 | Genoway | Cell and transgenic animal modelling human antigenic presentation and their uses |
| JP2008500014A (ja) | 2003-10-14 | 2008-01-10 | ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ・フェルトレーテン・デュルヒ・デン・プレジデンテン | 組換えワクチンおよびその使用 |
| JP2010510773A (ja) | 2006-11-24 | 2010-04-08 | アグリカルチュラル バイオテクノロジー センター | 免疫応答が向上したトランスジェニック動物及びその作製方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| DE69033493D1 (de) | 1989-07-25 | 2004-08-12 | Cell Genesys Inc | Homologe rekombination für universelle donorzellen und chimerische säugetierzellen |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| WO1993005817A1 (en) | 1991-09-19 | 1993-04-01 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | Transgenic non-human animals having targeted lymphocyte transduction genes. |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| WO1997032603A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| CA2325721A1 (en) * | 1998-03-30 | 1999-10-07 | Research Development Foundation | Corticotropin releasing factor receptor 1-deficient mice |
| WO2001027291A1 (en) | 1999-10-12 | 2001-04-19 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US7067308B1 (en) * | 2000-03-28 | 2006-06-27 | Bioagri Corporation | Vector for genetically modifying non-human animals |
| US20030124524A1 (en) | 2000-06-23 | 2003-07-03 | Kenneth Kornman | Screening assays for identifying modulators of the inflammatory or immune response |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JPWO2002047474A1 (ja) | 2000-12-13 | 2004-04-15 | 住友製薬株式会社 | Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用 |
| WO2002059263A2 (en) | 2000-12-19 | 2002-08-01 | Sunol Molecular Corporation | Transgenic animals comprising a humanized immune system |
| US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
| US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| US7745690B2 (en) | 2004-03-09 | 2010-06-29 | Nagoya Industrial Science Research Institute | Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| EP1878342A1 (en) * | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| TWI476280B (zh) | 2008-03-07 | 2015-03-11 | Regeneron Pharma | 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠 |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| EP3028565B1 (en) | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
| CN101695587B (zh) * | 2009-10-21 | 2012-08-29 | 上海中山医疗科技发展公司 | 一种基因修饰及调控的内皮祖细胞捕获支架的制备方法 |
| US9695410B2 (en) | 2010-07-15 | 2017-07-04 | Technion Research & Development Foundation Limited | Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides |
| WO2012039779A1 (en) | 2010-09-24 | 2012-03-29 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| SG10201510056SA (en) | 2011-10-28 | 2016-01-28 | Regeneron Pharma | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| CA2900832A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| JP6444321B2 (ja) | 2013-02-22 | 2018-12-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヒト化主要組織適合性遺伝子複合体を発現するマウス |
| AU2014249148B2 (en) | 2013-03-11 | 2020-04-02 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
| AU2016246698B2 (en) | 2015-04-06 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Humanized T cell mediated immune responses in non-human animals |
-
2012
- 2012-10-26 SG SG10201510056SA patent/SG10201510056SA/en unknown
- 2012-10-26 WO PCT/US2012/062029 patent/WO2013063340A1/en not_active Ceased
- 2012-10-26 MX MX2014004896A patent/MX355726B/es active IP Right Grant
- 2012-10-26 RS RS20220473A patent/RS63220B1/sr unknown
- 2012-10-26 RS RS20200224A patent/RS59997B1/sr unknown
- 2012-10-26 PT PT128061991T patent/PT2770822T/pt unknown
- 2012-10-26 HR HRP20171327TT patent/HRP20171327T1/hr unknown
- 2012-10-26 JP JP2014539027A patent/JP6285361B2/ja active Active
- 2012-10-26 PL PL17171524T patent/PL3272214T3/pl unknown
- 2012-10-26 CN CN201810239986.6A patent/CN108401986B/zh active Active
- 2012-10-26 ES ES19189533T patent/ES2914374T3/es active Active
- 2012-10-26 SI SI201231999T patent/SI3590332T1/sl unknown
- 2012-10-26 IN IN3892CHN2014 patent/IN2014CN03892A/en unknown
- 2012-10-26 MX MX2017013492A patent/MX379060B/es unknown
- 2012-10-26 EP EP12806199.1A patent/EP2770822B9/en active Active
- 2012-10-26 HU HUE12806199A patent/HUE034374T2/en unknown
- 2012-10-26 ES ES17171524T patent/ES2774488T3/es active Active
- 2012-10-26 LT LTEP12806199.1T patent/LT2770822T/lt unknown
- 2012-10-26 SM SM20220205T patent/SMT202200205T1/it unknown
- 2012-10-26 PT PT191895333T patent/PT3590332T/pt unknown
- 2012-10-26 US US13/661,116 patent/US8847005B2/en active Active
- 2012-10-26 CN CN201810239690.4A patent/CN108707608A/zh active Pending
- 2012-10-26 HU HUE17171524A patent/HUE048511T2/hu unknown
- 2012-10-26 AU AU2012327205A patent/AU2012327205B2/en active Active
- 2012-10-26 KR KR1020147014315A patent/KR101926442B1/ko active Active
- 2012-10-26 RU RU2014116577A patent/RU2660564C2/ru active
- 2012-10-26 PL PL12806199T patent/PL2770822T3/pl unknown
- 2012-10-26 CA CA2852962A patent/CA2852962C/en active Active
- 2012-10-26 SM SM20170437T patent/SMT201700437T1/it unknown
- 2012-10-26 PT PT171715246T patent/PT3272214T/pt unknown
- 2012-10-26 RS RS20170897A patent/RS56330B1/sr unknown
- 2012-10-26 CN CN201280065075.7A patent/CN104039133B/zh active Active
- 2012-10-26 PL PL19189533T patent/PL3590332T3/pl unknown
- 2012-10-26 SG SG10201909638U patent/SG10201909638UA/en unknown
- 2012-10-26 DK DK12806199.1T patent/DK2770822T3/en active
- 2012-10-26 KR KR1020187034955A patent/KR102113108B1/ko active Active
- 2012-10-26 SI SI201231056T patent/SI2770822T1/sl unknown
- 2012-10-26 DK DK19189533.3T patent/DK3590332T3/da active
- 2012-10-26 LT LTEP17171524.6T patent/LT3272214T/lt unknown
- 2012-10-26 HR HRP20220616TT patent/HRP20220616T1/hr unknown
- 2012-10-26 ES ES12806199.1T patent/ES2640241T3/es active Active
- 2012-10-26 EP EP22152099.2A patent/EP4052572B1/en active Active
- 2012-10-26 SG SG11201400938UA patent/SG11201400938UA/en unknown
- 2012-10-26 DK DK17171524.6T patent/DK3272214T3/da active
- 2012-10-26 LT LTEP19189533.3T patent/LT3590332T/lt unknown
- 2012-10-26 EP EP19189533.3A patent/EP3590332B1/en active Active
- 2012-10-26 SI SI201231738T patent/SI3272214T1/sl unknown
- 2012-10-26 SM SM20200114T patent/SMT202000114T1/it unknown
- 2012-10-26 BR BR112014009941-3A patent/BR112014009941B1/pt active IP Right Grant
- 2012-10-26 EP EP17171524.6A patent/EP3272214B1/en active Active
-
2014
- 2014-04-03 IL IL231895A patent/IL231895B/en active IP Right Grant
- 2014-08-08 US US14/455,237 patent/US9585373B2/en active Active
-
2016
- 2016-01-11 IL IL243565A patent/IL243565A/en active IP Right Grant
- 2016-04-13 AU AU2016202317A patent/AU2016202317B2/en active Active
-
2017
- 2017-01-24 US US15/413,785 patent/US10219493B2/en active Active
- 2017-08-17 JP JP2017157497A patent/JP6652529B2/ja active Active
- 2017-09-05 CY CY20171100934T patent/CY1119283T1/el unknown
-
2018
- 2018-02-27 AU AU2018201402A patent/AU2018201402C1/en active Active
- 2018-06-21 IL IL260209A patent/IL260209B/en active IP Right Grant
-
2019
- 2019-01-10 US US16/244,912 patent/US10986822B2/en active Active
- 2019-01-10 US US16/244,892 patent/US11219195B2/en active Active
-
2020
- 2020-02-24 HR HRP20200305TT patent/HRP20200305T1/hr unknown
- 2020-02-26 CY CY20201100178T patent/CY1122700T1/el unknown
-
2021
- 2021-01-22 AU AU2021200438A patent/AU2021200438B2/en active Active
- 2021-03-17 US US17/204,526 patent/US20210195878A1/en not_active Abandoned
-
2022
- 2022-05-20 CY CY20221100349T patent/CY1125196T1/el unknown
-
2024
- 2024-07-23 US US18/781,796 patent/US20240365761A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070209083A1 (en) | 2001-07-13 | 2007-09-06 | Genoway | Cell and transgenic animal modelling human antigenic presentation and their uses |
| JP2008500014A (ja) | 2003-10-14 | 2008-01-10 | ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ・フェルトレーテン・デュルヒ・デン・プレジデンテン | 組換えワクチンおよびその使用 |
| JP2010510773A (ja) | 2006-11-24 | 2010-04-08 | アグリカルチュラル バイオテクノロジー センター | 免疫応答が向上したトランスジェニック動物及びその作製方法 |
Non-Patent Citations (2)
| Title |
|---|
| J. Exp. Med., vol.183, pp.2635-2644.(1996) |
| PNAS, vol.91, pp.6151-6155(1994). |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240365761A1 (en) | Genetically modified major histocompatibility complex mice | |
| US9700025B2 (en) | Genetically modified major histocompatibility complex animals | |
| KR102309653B1 (ko) | 키메라 주요 조직적합성 복합체 （ｍｈｃ） 제ｉｉ부류 분자를 발현하는 유전자전이 마우스 | |
| HK40093866A (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules | |
| HK40080877A (en) | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules | |
| RU2797549C2 (ru) | Генетически модифицированные мыши, экспрессирующие химерные молекулы главного комплекса гистосовместимости | |
| HK1250131B (en) | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules | |
| HK1213144B (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules | |
| NZ717130B2 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20140527 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20171026 Comment text: Request for Examination of Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20171026 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20171229 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20180531 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20180831 |
|
| A107 | Divisional application of patent | ||
| GRNT | Written decision to grant | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20181203 |
|
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20181203 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20181204 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20211122 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20221123 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20231128 Start annual number: 6 End annual number: 6 |